SHENZHEN, China, July 14, 2026 /PRNewswire/ -- Tencent Music Entertainment Group ("TME", or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, today announced that it will report its unaudited financial results for the second quarter of 2026 before the U.S. market opens on Tuesday, August 11, 2026.

TME's management will host a Tencent Meeting Webinar on Tuesday, August 11, 2026, at 7:00 A.M. Eastern Time or 7:00 P.M. Beijing/Hong Kong Time on Tuesday, August 11, 2026, to review and discuss the Company's business and financial performance.

For participants who wish to join the Tencent Meeting Webinar, please complete online registration in advance using the links provided below. Upon registration, each participant will receive an email with webinar access information, including meeting ID, meeting link, dial-in numbers, and a unique attendee ID to join the webinar.

Participant Online Registration

Chinese Mainland^[1]: https://meeting.tencent.com/dw/taPIQDShxiVQ
International:             https://voovmeeting.com/dw/taPIQDShxiVQ

A live and archived webcast of the webinar will also be available at the Company's investor relations website at https://ir.tencentmusic.com/.

^[1] Chinese Mainland, for the purpose of this announcement only, excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region of the People's Republic of China and Taiwan

About Tencent Music Entertainment

Tencent Music Entertainment Group (NYSE: TME and HKEX: 1698) is the leading online music and audio entertainment platform in China, operating the country's highly popular and innovative music apps: QQ Music, Kugou Music, Kuwo Music and WeSing. TME's mission is to create endless possibilities with music and technology. TME's platform comprises online music, online audio, online karaoke, music-centric live streaming and online concert services, enabling music fans to discover, listen, sing, watch, perform and socialize around music. For more information, please visit ir.tencentmusic.com.

Investor Relations Contact
Tencent Music Entertainment Group
[email protected]  
+86 (755) 8601-3388 ext. 885034

HONG KONG, July 14, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study evaluating a cadonilimab-based combination regimen for the perioperative treatment of locally advanced, resectable HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. Cadonilimab is the world's first PD-1/CTLA-4 bispecific antibody developed by Akeso.

The study is being led by Dr. Yelena Janjigian, a globally renowned expert in gastrointestinal malignancies at MSKCC. It is now actively enrolling patients across the United States.

This Phase II study will generate robust clinical evidence to support the future initiation of an international multicenter Phase III trial of the cadonilimab combination regimen for the perioperative treatment of GC/GEJ adenocarcinoma.

Cadonilimab and ivonescimab, as first-in-class bispecific antibodies with breakthrough global clinical value, have garnered significant attention and recognition from the international medical community. These innovative IO 2.0 therapies are increasingly favored by global partners as the preferred backbone for combination regimens and novel treatment paradigms across a wide range of cancers. Their global therapeutic value continues to be scientifically explored and realized through ongoing clinical data and new studies.

Building on cadonilimab's unique dual-target synergistic mechanism, this Phase II study is supported by strong evidence from the Phase III COMPASSION-15 trial and previous Phase II neoadjuvant studies in gastric/GEJ adenocarcinoma.

Gastric cancer is the fifth most common malignancy worldwide, with nearly one million new cases annually. For patients with locally advanced, resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma, standard perioperative FLOT chemotherapy achieves a 3-year overall survival rate of only 48%. Although the addition of PD-1 inhibitors to FLOT has become the new standard of care, the pathologic complete response (pCR) rate remains limited at approximately 19%, and nearly one-third of patients experience disease recurrence or death within two years. Dual PD-1/CTLA-4 inhibition has shown limited benefit due to overlapping toxicities and increased early mortality. A significant unmet medical need persists for more effective and better-tolerated treatment options.

As the first approved bispecific antibody for cancer immunotherapy, cadonilimab has demonstrated breakthrough clinical benefits across multiple pivotal studies and is now widely used in clinical practice. More than 12 registrational or Phase III studies of cadonilimab are currently underway globally, including two international multicenter registrational/Phase III trials led by Akeso.

In addition, Akeso is collaborating with INOVIO to explore a novel combination regimen using INOVIO's DNA-based therapy for glioblastoma (GBM) at Dana-Farber Cancer Institute and Mass General Brigham. The Company continues to accelerate the global development of cadonilimab through strategic partnerships with leading therapeutics and institutions.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, 27 candidates have advanced into clinical trials—including 15 bispecific or multispecific antibodies and bispecific ADCs—and 8 innovative drugs have reached commercial stage.

Through efficient and groundbreaking R&D, Akeso integrates premier global resources to develop transformative medicines, deliver high-quality, affordable therapeutic antibodies to patients worldwide, and generate sustained commercial and societal value as it strives to become a global leader in biopharmaceutical innovation.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

Counterpoint Research's latest report showed that global smartphone shipments sank 11% in the second quarter, hitting the lowest level since 2013, as prolonged memory chip shortages pushed up handset prices and suppressed demand.

During the period, iPhone shipments of Apple Inc. (AAPL.US) grew 3%, giving the company a global market share of 20%. Samsung regained the top spot with a 24% market share and recorded the strongest growth among the top five brands, driven by robust sales of its flagship Galaxy S26 series. XIAOMI-W (01810.HK) ranked third with a 12% market share, followed by OPPO (11%) and vivo (8%).
~

AASTOCKS Financial News
Website: www.aastocks.com

Due to substandard product quality, NVIDIA Corporation (NVDA.US) may stop cooperating with VGT (02476.HK) after evaluation, involving order amounts of RMB5 billion, according to market talks.

VGT issued an announcement to clarify that recent online rumors regarding the company's products, market share and project progress were seriously inconsistent with facts. The company emphasized that it is a long-term strategic partner of leading domestic and overseas AI clients, and has always regarded quality and safety as its lifeline while strictly managing operations according to client standards.

VGT stated that demand for AI-related PCB products remains strong, with orders on hand continuing to grow, while production and shipments are operating normally. Orders from major clients continue to increase, and the company has maintained close communication with core clients. Iterative products jointly developed through cooperation are progressing smoothly, while some clients have already released long-term demand projections for 2027 to 2028. Management expressed full confidence in subsequent production operations and profit realization.

The group said false rumors spread through online platforms and WeChat groups have adversely affected its reputation and normal business operations, seriously misleading investors. The company will reserve the right to pursue liabilities through legal channels.
~

AASTOCKS Financial News
Website: www.aastocks.com

Iran announced the indefinite closure of the Strait of Hormuz, while the US military attacked Iran for the fourth time within a week, sending international oil prices up more than 3%.

Futures for the three major US stock indices were mixed. DJIA futures edged up 6 points, while S&P 500 futures and Nasdaq futures lost 0.35% and 1.15%, respectively. South Korean stocks plunged 9%, while US chip and memory stocks came under pressure in pre-market trading. Micron Technology, Inc. (MU.US) dived 5.5% pre-market. Sandisk Corporation (SNDK.US), Western Digital Corporation (WDC.US) and Seagate (STX.US) shed 4.8-7% pre-market. Marvell Technology, Inc. (MRVL.US), Advanced Micro Devices, Inc. (AMD.US), Intel Corporation (INTC.US), QUALCOMM Incorporated (QCOM.US) and NVIDIA Corporation (NVDA.US) faded 1.9-3.1% pre-market.

Major Asia-Pacific stock markets generally declined today (13th). China's three major A-share indices closed down between 2.1% and 3.5%. Hong Kong stocks gained 38 points, or less than 0.2%, to close at 24,213 points, with turnover of HKD309.515 billion. Japan's Nikkei closed down 1,315 points, or 1.9%, at 67,242. South Korea's Kospi closed down 669 points, or 8.95%, at 6,806, marking a more than two-month low and triggering the seventh circuit breaker this year. Samsung Electronics plunged 10.7%, while SK Hynix tumbled 15.4%, marking the stock's biggest single-day decline on record. SK Hynix ADR, which was listed in the US last Friday, closed at USD168.01, 12.8% above its offer price. UBS previously issued a report recommending buying SK Hynix ADR while short-selling its listed South Korean shares.

European stocks were mixed in early Monday trading. The pan-European STOXX 600 fell 0.2% to 639.82. The UK's FTSE 100 edged down 0.1% to 10,486. France's CAC dipped 0.15% to 8,326. Germany's DAX added 0.1% to 25,087. Italy's FTSE MIB hiked 0.1% to 52,660. Spain's IBEX 35 sank 0.2% to 19,352.
~

AASTOCKS Financial News
Website: www.aastocks.com

Samsung Foundry Chief Engineer James Kim said Samsung Electronics has completed the design of Tesla (TSLA.US)'s AI5 autonomous driving system chips, which will adopt Samsung's latest 2-nm process technology and are expected to begin production soon at its Texas foundry plant.

The chips are currently in the tape-out stage, marking the finalization of the design and the start of engineering sample production.
~

AASTOCKS Financial News
Website: www.aastocks.com

HONG KONG, July 13, 2026 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) announced that its healthcare subsidiary, KLN Medical Limited ('KLN Medical'), has signed a tripartite Memorandum of Understanding (MOU) with Advantech Co., Ltd. ('Advantech'; Stock Code 2395.TW), a global leader in IoT intelligent systems and embedded platforms, and YDCare, a medical nursing brand under New Frontier Group. Under the MOU, KLN Medical will be the sole distributor of Advantech's iWard smart ward solutions ('iWard') for the Hong Kong market. The partnership aims to synergise the three parties' expertise across smart healthcare technology, clinical application and medical supply chain management to support the digital transformation of Hong Kong's healthcare system and promote the application and development of advanced healthtech.

KLN Medical will leverage its combined strengths in healthcare supply chain management, technical capabilities and after-market support to provide medical institutions with one-stop solutions covering equipment delivery, after-sales technical support, maintenance services and system implementation co-ordination, fully supporting the smooth deployment and long-term development of iWard in Hong Kong. Through iWard's integration of patient information, clinical workflows and medical equipment and seamless connection with the existing information systems of medical institutions, together with YDCare's expertise in clinical application, the three parties will work together to help healthcare teams enhance clinical collaboration efficiency and ward operation management, drive the development of smart wards and the digitalisation of clinical workflows and create greater value for healthcare professionals and patients.

Samuel Lau, Managing Director - Integrated Logistics of KLN, said, "We are pleased to enter this tripartite partnership with Advantech and YDCare, which marks an important milestone for our expansion into the smart healthcare sector. With our professional expertise, extensive healthcare logistics network and commitment to service excellence, we will provide Hong Kong's medical institutions with efficient and reliable supply chain solutions."

Jackson Hsu, PD Head of Advantech, said, "The iWard solutions have gained recognition in multiple Asian healthcare markets including the Chinese Mainland, Thailand and Japan. We look forward to introducing this proven and reliable technology to Hong Kong in collaboration with KLN Medical and YDCare, with a view to advancing medical digitalisation. This will provide efficient operational support for frontline medical professionals and enhance the patient care experience."

Serena Xie, Founder and CEO of YDCare, said, "YDCare has been dedicated to providing home nursing care services for a decade and is one of the pioneers in home-based healthcare in Hong Kong. With our clinical perspective, professional experience and nursing best practices, we will integrate patient data with the intelligent systems. We hope this collaboration will help more medical institutions optimise nursing workflows and further improve the quality and safety of patient care."

Looking ahead, KLN Medical will continue to partner with industry leaders to deliver innovative medical technologies and promote a smarter healthcare ecosystem. 

-End-

About KLN Logistics Group Limited (Stock Code 0636.HK)

KLN is an Asia-rooted, global 3PL delivering customer-centric, end-to-end supply chain solutions that connect markets and power global trade, as a trusted partner to many of the top 100 global brands and Fortune Global 500 companies across a wide spectrum of industries. With a presence across 58 countries and territories, KLN offers integrated logistics, international freight forwarding, e-commerce and industrial project logistics solutions. KLN has been the global No. 1 Trans-Pacific NVOCC from Asia to the US since 2023 and ranks No. 20 among Global 3PLs (Armstrong & Associates, 2026). Listed on the Hong Kong Stock Exchange, KLN generated revenue* of over HK$56 billion in 2025 and is a constituent of the Hang Seng Corporate Sustainability Benchmark Index. Learn more at www.kln.com

* For continuing operations only

About KLN Medical Limited

KLN Medical is dedicated to advancing healthcare in Hong Kong and Southeast Asia by delivering innovative medical technologies that improve patient outcomes. In collaboration with world-renowned partners, KLN Medical ensures that healthcare professionals have access to the latest advancements, driving excellence across the continuum of care. As a member of the KLN Group, KLN Medical focuses on the reliable distribution of high-quality medical devices and solutions. Its multidisciplinary team brings deep expertise across key areas including cardiovascular care, rehabilitation, hospital and clinic support, engineering, marketing, business development, regulatory affairs and quality assurance, customer service, and operations. Website: www.medical.kln.com

About Advantech Co., Ltd

Advantech is a global leader in IoT intelligent systems and embedded platforms, with the corporate vision of "Enabling an Intelligent Planet." To embrace the trends of edge computing and artificial intelligence, Advantech fully deploys its sector-driven strategy and focus on Edge Computing and Edge AI, targeting five key markets: Edge Intelligence Systems, Manufacturing, Energy and Utilities, iHealthcare, and iCity Services & iRetail. In the meantime, Advantech is enhancing its global presence and core competitiveness by integrating its Edge Computing hardware platform, the WISE-IoT software platform, and sector-specific Edge AI solutions with domain expertise. The integration will form an "Orchestration" model for seamless industrial chain connections, benefiting both partners and clients. Advantech is also working with business partners to co-create business ecosystems that accelerate the goal of industrial intelligence. Website: https://www.advantech.com/zh-tw

About YDCare

YDCare is the flagship home care brand of New Frontier Group. Backed by the Group's premium medical resources, YDCare continuously enhances its personalised, comprehensive, and tiered professional services to meet the diverse home care needs of both the elderly and children in China. Led by senior nursing experts and a multidisciplinary team, its Hong Kong & International business line is dedicated to extending hospital-grade safety standards and clinical workflows into the home environment. The platform delivers a one-stop service encompassing medical nursing, daily care, home rehabilitation, palliative and end-of-life care, and medical equipment rental. Notably, YDCare pioneers advanced medical technologies in Hong Kong's home settings, including Negative Pressure Wound Therapy (NPWT) and Home Parenteral Nutrition (HPN), enabling patients to recover safely in familiar surroundings while effectively reducing unnecessary hospitalisations and commutes. Website: www.ydcarehk.com

香港, 2026年7月13日 /美通社/ -- KLN Logistics Group Limited（「KLN」；股份代號0636.HK）欣然宣布，旗下醫療保健業務附屬公司KLN Medical Limited （「KLN Medical」）與全球物聯網系統及嵌入式平台領導供應商研華股份有限公司（「研華」；股份代號2395.TW）和新風天域集團旗下醫療護理品牌YDCare易得康（「易得康」）簽署三方合作備忘錄。根據合作備忘錄，KLN Medical將成為研華iWard智慧病房解決方案（「iWard」）於香港市場的獨家經銷商。是次合作旨在結合三方於智慧醫療科技、臨床應用及醫療供應鏈管理方面的專業能力，支持香港醫療體系數碼轉型，促進智慧醫療技術的應用及發展。

KLN Medical 將充分發揮其醫療供應鏈管理、專業技術及售後支援的綜合優勢，為香港醫療機構提供涵蓋設備配送、售後技術支援、維護服務及系統導入協調等一站式服務，全面支援iWard於香港市場的順利部署及長遠發展。透過iWard整合病人資訊、臨床工作流程及醫療設備，並與醫療機構現有資訊系統無縫整合，同時結合易得康在臨床應用的專業能力，三方將攜手協助醫護團隊提升臨床協作效率及病房營運管理水平，推動智慧病房建設及臨床工作流程數碼化，為醫護人員及病人創造更高價值。

KLN綜合物流總裁劉健培表示：「我們很高興與研華及易得康達成三方夥伴合作，此次合作是我們拓展智慧醫療領域的重要里程碑。憑藉專業的能力與完善的醫療物流網絡優勢，以及對卓越服務的承諾，我們將為香港醫療機構提供高效可靠的供應鏈解決方案。」

研華智慧醫療解決方案事業部負責人許全慶表示：「iWard智慧病房解決方案已應用於中國內地、泰國及日本等亞洲醫療市場並獲得肯定。我們期待將成熟可靠的技術引入香港，與KLN Medical及易得康合力促進醫療數碼化發展，為前線醫護提供高效的工作支援，同時為病人帶來更優質的護理體驗。」

易得康聯合創始人兼首席執行官謝韞之表示：「易得康深耕居家護理服務十年，更是香港居家醫療護理的先行者之一，我們將從臨床專業視角出發，結合專業經驗與護理標準，將病人數據與智能系統整合，期望這次三方合作能協助更多醫療機構優化護理流程，進一步提升護理品質及安全。」

展望未來，KLN Medical將繼續與業界領袖合作，引進創新的醫療科技，推動更智慧的醫療生態系統。

-完-

關於KLN Logistics Group Limited（股份代號0636.HK）

KLN是紮根亞洲的國際第三方物流服務供應商，致力提供以客戶為中心的端到端供應鏈解決方案，連繫各地市場，促進環球貿易，為全球眾多百強品牌及《財富》世界500強企業在不同行業所信賴的合作夥伴。KLN 的辦事處遍布全球58 個國家及地區，業務涵蓋綜合物流、國際貨運、以及電子商貿和工業項目物流等。KLN自2023年起為全球第一大亞洲至美國跨太平洋貿易航線無船承運商，以及在全球第三方物流供應商中排名第20位（Armstrong & Associates，2026年）。KLN於香港聯合交易所上市，2025 年收入*逾 560 億港元，並為恒生可持續發展企業基準指數成份股。了解更多，請瀏覽：www.kln.com  

* 僅就持續經營業務而言

關於KLN Medical Limited

KLN Medical 致力推動香港及東南亞地區的醫療發展，提供創新醫療科技，提升病人治療成效。憑藉與多個國際知名品牌的合作，KLN Medical 協助醫療專業人員掌握最新醫療技術，全面提升醫療質素。作為 KLN 集團旗下成員，KLN Medical 專注於高品質醫療器材與解決方案的穩定分銷。其多元化團隊在多個專業範疇具備深厚經驗，包括心血管護理、復康支援、醫院及診所運作、工程、行銷、市場拓展、法規事務與品質保證、客戶服務及營運管理等。網站連結：www.medical.kln.com

關於研華股份有限公司

研華為全球物聯網智能系統與嵌入式平台領導廠商，並以「智能地球的推手」作為企業品牌願景。為迎接邊緣運算與人工智慧之大趨勢，研華以Sector Driven策略全面展開佈署，並將以Edge Computing和Edge AI為核心，聚焦邊緣智能系統、智慧製造、能源與公共事業、智能醫療、智能零售與服務等五大關鍵市場，加強全球布局提升核心競爭力；整合Edge Computing邊緣硬體平台產品群、工業物聯網軟體平台WISE-IoT，再加入產業Edge AI解決方案及行業知識，重塑成產業整合應用的協同共譜之經營模式，助力夥伴客戶串接產業鏈；此外，亦積極偕同各產業夥伴「共創」產業生態圈，以加速實踐產業智能化之目標。網站連結：https://www.advantech.com/zh-tw

關於易得康

「易得康」是新風天域集團旗下的居家護理核心品牌，依托集團的優質醫療資源，持續升級個性化、全方位的分層專業服務供給體系，專注於滿足中國「一老一小」多元化的居家護理需求。其香港及國際業務品牌「YDCare」由資深護理專家領銜，匯聚多學科專業人才，致力於將醫院級安全標準與臨床流程延伸至家中。平台不僅提供醫療護理、生活照顧、居家康復、安寧療護及醫療設備租賃的一站式服務，更率先在香港居家場景中引入負壓傷口治療（NPWT）、靜脈營養治療（HPN）等前沿醫療技術，讓患者在熟悉的環境中安心康復，有效減少不必要的住院與往返醫院。網站連結：www.ydcarehk.com

Lei Jun, founder of XIAOMI-W (01810.HK), said Xiaomi Auto will enter the European market next year. Earlier reports said Xiaomi hired Dieter Lorenz, former Senior Manager of Delivery Operations for Central Europe at Tesla, Inc. (TSLA.US), in April as the company's head of European delivery and logistics.

Furthermore, Lei revealed that the new-generation SU7 became the best-selling sedan priced above RMB200,000 in June.

XIAOMI-W last stood at HKD25.92 today (13th), up 0.31%, with trading volume of 114 million shares and turnover of HKD2.986 billion.
~

AASTOCKS Financial News
Website: www.aastocks.com

SK hynix Inc. (SKHY.US) was listed on Nasdaq last Friday (10th), closing at USD168.01, 12.8% above its offering price. SK hynix Inc. CEO Kwak Noh-Jung said the global memory chip industry will face the most severe supply shortage in history in 2027. Despite the company's aggressive capacity expansion, memory demand is expected to continue exceeding the company's production capacity over the next decade.

He said that from a supply perspective, next year will be the worst year in the industry's history, as customer demand continues to grow while the company's production capacity remains limited. The US, Japan and SE Asia remain candidate locations for future wafer fabrication investments, and the company will prioritize locations capable of providing sufficient land, electricity, water resources and skilled labor at competitive manufacturing costs.
~

AASTOCKS Financial News
Website: www.aastocks.com